The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.
Geron Corp. (Nasdaq: GERN): Stock of the Day
by Katharine Schildt, Assistant Editor, The Oxford Club
A New Era for Stem Cell Research
Stem cell research has been a controversial subject for quite some time. And it’s been no secret that the Bush administration wasn’t a big fan. But just days after President Obama’s inauguration, a huge breakthrough has already been made in the administrative logjam.
Obama officially relaxed the restrictions on federal funding of stem cell research, which has sent shares of this biopharmaceutical company soaring.
Geron Corp. (Nasdaq: GERN), based in the United States, is the premiere developer of biopharmaceuticals for the treatment of certain cancers, as well as degenerative diseases such as spinal cord injury and diabetes.
Already a global leader in the development of embryonic stem cell-based therapies, the U.S. Food and Drug Administration (FDA) has now approved Geron to start the first clinical trial on humans with spinal cord injuries using its GRNOPC1.
“The company gained federal permission this week to inject eight to 10 patients with cells derived from embryonic cells,” said the president and CEO of Geron Corp., Dr. Thomas Okarma.
Geron is the first and only company to get such clearance – giving them a clear lead in the biopharmaceuticals field. And this lead is demonstrated in their stock price. Upon the release of this news on Friday, shares promptly jumped nearly 36%.
“This marks the beginning of what is potentially a new chapter in medical therapeutics – one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells,” said Okarma.
Geron To Begin Treating Spinal Cord Injuries
Geron’s most advanced human embryonic stem cell (hESCs) product is the GRNOPC1, which is designed specifically for the treatment of spinal cord injury. In previous stem cell trials, animals with injuries showed improved motor ability and use of previously paralyzed legs. It also caused damaged cells to repair themselves, regenerating healthy tissue.
The clinical trials on humans will take place in four to seven medical centers beginning this summer. The hope is to improve mobility so that the patients can participate in physical therapy, improving their mobility and quality of life.
Geron has other hESC-based products coming down the pipeline as well. The need for such therapies, and the real impact on the lives of millions, is why this new era of stem cell research is so exciting and promising.
The newfound government stem cell push, coupled with Geron’s exclusive rights to several cell types, gives this company a lot of potential. And if that potential is anything like what we’ve already seen, investors should be very happy.
- Geron Corp (Nasdaq: GERN): Stock of the Day
- The Next Big Thing in Health Care: How to Profit From Immunotherapy & Regenerative Medicine
- Dendreon’s Reached Orbit… Now Who’s Next?
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed